The Tuesday approval of the Merck drug covers the treatment of adults whose pulmonary arterial hypertension (PAH) is at intermediate or high risk of progression.
Winrevair is based on research indicating that an imbalance in cell signaling leads to the proliferation of cells that thicken the insides of pulmonary vessels.
[
add
]
[
|
|
...
]